ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
0.3360 USD   -3.75%
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
GL
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
AQ
05/09HC Wainwright Trims Eloxx Pharmaceuticals Price Target to $0.5 From $1, Maintains Neutral Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, each designed to be a eukaryotic ribosomal selective glycoside (ERSG), formulated to treat rare and ultra-rare premature stop codon diseases. The Company's lead product candidate, ELX-02, is a small molecule designed to restore production of full-length functional proteins. ELX-02 is in clinical development for systemic administration for cystic fibrosis. The Company is also conducting investigational new drug (IND)-enabling preclinical studies of ERSG compounds for autosomal dominant polycystic kidney disease (ADPKD) and in rare inherited retinal disorders (IRDs) by intravitreal administration with an initial focus on Usher Syndrome. Its preclinical candidate pool consists of a library of ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

Number of employees : 28 people.
Managers
Name Title Age Since
Sumit Aggarwal President, Chief Executive Officer & Director - 2021
Daniel E. Geffken Chief Financial & Accounting Officer 64 2021
Vijay Modur, Dr. Head-Research & Development - 2021
Ali Hariri, Dr. Chief Medical Officer - 2021
Barbara Ryan Investor Relations Contact - -
Deborah Peirce Vice President-Human Resources - 2021
Members of the board
Name Title Age Since
Tomer Kariv Chairman 60 2020
Ran Nussbaum Independent Director 49 2017
Gadi Veinrib Independent Director 42 2017
Zafrira Avnur, Dr. Independent Director 70 2017
Jasbir S. Seehra, Dr. Independent Director 65 2018
Steven D. Rubin Independent Director 61 2014
Alan E. Walts, Dr. Independent Director 61 2021
Raj Parekh Independent Director 60 2021
Sumit Aggarwal President, Chief Executive Officer & Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 87,074,455 76,058,997 87.3% 421,366 0.5% 87.3%
Shareholders
NameEquities%
Pontifax Management Co. Ltd. 15,265,590 17.6%
Advent Venture Partners LLP 4,998,936 5.77%
Roche Holding AG 4,998,936 5.77%
Gurnet Point Capital LLC 4,976,714 5.74%
The Vanguard Group, Inc. 2,996,783 3.46%
LSP Management Group BV 2,953,673 3.41%
Menora Mivtachim Insurance Ltd. 2,094,208 2.42%
SilverArc Capital Management LLC 1,930,092 2.23%
American Money Management Corp. 1,480,000 1.71%
Harel Mutual Funds Ltd. 1,176,401 1.36%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Eloxx Pharmaceuticals, Inc.